In conjunction with the issuance of the press release, management will host a conference call at 4:30 p.m. ET on Thursday, August 3, 2006 to discuss the company's financial results for the second quarter 2006, clinical programs and financial guidance.
To listen to a live audio webcast of the call, go to "Calendar of Events" in the Idenix Investor Center at http://www.idenix.com. A replay of the call will also be available from 8:00 p.m. ET on August 3, 2006 until 8:00 p.m. ET on August 17, 2006. To access the replay, please dial 800-642-1687 or 706-645-9291 (international), and provide the access code 2317379. An archived webcast will also be available on the Idenix website for two weeks after the call.
Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis B virus, hepatitis C virus and human immunodeficiency virus. Idenix's headquarters are located in Cambridge, Massachusetts and it has drug discovery operations in Montpellier, France and Cagliari, Italy. For more information on Idenix, please visit http://www.idenix.com.
Contact:
Idenix Pharmaceuticals, Inc.
Investors: Amy Sullivan (617) 995-9838
Source: Idenix Pharmaceuticals, Inc.
